SCHEMBL23200475

SCHEMBL23200475

C[C@H](n1cnc2c(N)nc3ccccc3c21)C1(O)CCCC1

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TLR7 Q9NYK1 15/20 0.53
LMNA P02545 1/20 0.53
POLB P06746 1/20 0.53
HRH2 P25021 1/20 0.53
ADRA1D P25100 1/20 0.53
HTR2A P28223 1/20 0.53
ADORA2A P29274 1/20 0.53
ADRA1A P35348 1/20 0.53
NUDT1 P36639 1/20 0.53
HTR2B P41595 1/20 0.53
PDE4D Q08499 1/20 0.53
KCNH2 Q12809 1/20 0.53
TLR8 Q9NR97 6/20 0.41
CDK1 P06493 3/20 0.39
CCNB1 P14635 3/20 0.39
CCNE1 P24864 1/20 0.36
CDK2 P24941 1/20 0.36
USP5 P45974 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23200470 1.00 TLR7 (0.53) TLR7LMNAPOLBHRH2ADRA1D
SCHEMBL30543563 1.00 TLR7 (0.53) TLR7LMNAPOLBHRH2ADRA1D
SCHEMBL23200469 1.00 TLR7 (0.53) TLR7LMNAPOLBHRH2ADRA1D
SCHEMBL23200467 0.89 TLR7 (0.53) TLR7LMNAPOLBHRH2ADRA1D
SCHEMBL23200468 0.89 TLR7 (0.53) TLR7LMNAPOLBHRH2ADRA1D
SCHEMBL23200472 0.86 TLR7 (0.50) TLR7LMNAPOLBHRH2ADRA1D
SCHEMBL23909477 0.86 TLR7 (0.50) TLR7LMNAPOLBHRH2ADRA1D
SCHEMBL29789613 0.86 TLR7 (0.50) TLR7LMNAPOLBHRH2ADRA1D
SCHEMBL23200473 0.86 TLR7 (0.50) TLR7LMNAPOLBHRH2ADRA1D
SCHEMBL30543570 0.86 TLR7 (0.50) TLR7LMNAPOLBHRH2ADRA1D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12398134-B2 N-1 branched cycloalkyl substituted imidazo[4,5-c]quinoline compounds, compositions, and methods SOLVENTUM INTELLECTUAL PROPERTIES COMPANY (US) 2025-08-26 US disclosed
US-20240140946-A1 N-1 BRANCHED CYCLOALKYL SUBSTITUTED IMIDAZO[4,5-c]QUINOLINE COMPOUNDS, COMPOSITIONS, AND METHODS SOLVENTUM INTELLECTUAL PROPERTIES COMPANY 2024-05-02 US disclosed
US-11884662-B2 N-1 branched cycloalkyl substituted imidazo[4,5-c]quinoline compounds, compositions, and methods 3M INNOVATIVE PROPERTIES COMPANY (US) 2024-01-30 US disclosed
CN-112218864-B N-1 branched cycloalkyl substituted imidazo [4,5-c ] quinoline compounds, compositions and methods 3M创新有限公司 2023-09-08 CN disclosed
EP-3802536-B1 N-1 BRANCHED CYCLOALKYL SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE COMPOUNDS, COMPOSITIONS, AND METHODS 3M INNOVATIVE PROPERTIES CO (US) 2022-07-13 EP disclosed
EP-3802536-B1 N-1 BRANCHED CYCLOALKYL SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE COMPOUNDS, COMPOSITIONS, AND METHODS 3M INNOVATIVE PROPERTIES CO (US) 2022-07-13 EP disclosed
US-20210317116-A1 N-1 BRANCHED CYCLOALKYL SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE COMPOUNDS, COMPOSITIONS, AND METHODS SOLVENTUM INTELLECTUAL PROPERTIES COMPANY 2021-10-14 US disclosed
US-20210317116-A1 N-1 BRANCHED CYCLOALKYL SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE COMPOUNDS, COMPOSITIONS, AND METHODS SOLVENTUM INTELLECTUAL PROPERTIES COMPANY 2021-10-14 US disclosed
EP-3802536-A1 N-1 BRANCHED CYCLOALKYL SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE COMPOUNDS, COMPOSITIONS, AND METHODS 3M Innovative Properties Company (US) 2021-04-14 EP disclosed
CN-112218864-A N-1 branched cycloalkyl substituted imidazo [4,5-c ] quinoline compounds, compositions, and methods 3M创新有限公司 2021-01-12 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210317116-A1 N-1 BRANCHED CYCLOALKYL SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE COMPOUNDS, COMPOSITIONS, AND METHODS IFNG, IFNAR1, CCL5 TLR7 45/4885LMNA 2288/4885POLB 939/4885
US-11884662-B2 N-1 branched cycloalkyl substituted imidazo[4,5-c]quinoline compounds, compositions, and methods IFNG, IFNAR1, CCL5 TLR7 45/4885LMNA 2288/4885POLB 939/4885
US-12398134-B2 N-1 branched cycloalkyl substituted imidazo[4,5-c]quinoline compounds, compositions, and methods IFNG, IFNAR1, CCL5 TLR7 46/4885LMNA 2147/4885POLB 877/4885
US-20240140946-A1 N-1 BRANCHED CYCLOALKYL SUBSTITUTED IMIDAZO[4,5-c]QUINOLINE COMPOUNDS, COMPOSITIONS, AND METHODS IFNG, IFNAR1, CCL5 TLR7 46/4885LMNA 2147/4885POLB 877/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.